A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278.
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
At a glance
- Drugs GSK 356278 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 27 Apr 2012 Actual number of patients changed from 20 to 33 as reported by ClinicalTrials.gov record.
- 20 Apr 2012 Actual patient number is 20 according to ClinicalTrials.gov.
- 20 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.